Loading...
Market
Story
Alumis Announces $316 Million IPO, Seeks $1 Billion Valuation
Jun 24, 2024, 02:50 PM
Alumis, an immunology biotech company, has announced its initial public offering (IPO) of 17.65 million shares priced between $16 and $18 per share. The company aims to raise $300 million through this IPO, which will support its TYK2 inhibitor through phase 3 psoriasis trials. Alumis is seeking a valuation of up to $1 billion in the US market. The proceeds from the planned IPO, tagged at $316 million, will also help fund a late-stage clinical trial for psoriasis.
View original story
Similar markets
Above $300 million • 33%
Between $200 million and $300 million • 34%
Below $200 million • 33%
Less than $50M • 25%
$50M to $100M • 25%
$100M to $200M • 25%
More than $200M • 25%
Less than $6 billion • 25%
$6 billion to $7 billion • 25%
$7 billion to $8 billion • 25%
More than $8 billion • 25%
Less than $5 billion • 25%
$5 billion to $7 billion • 25%
$7 billion to $10 billion • 25%
More than $10 billion • 25%
Below $17 • 25%
$17 to $18.99 • 25%
$19 to $20.99 • 25%
$21 or more • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $30 billion • 25%
$30 billion to less than $40 billion • 25%
$40 billion to less than $50 billion • 25%
$50 billion or more • 25%
$30 billion to $39.9 billion • 25%
$40 billion to $49.9 billion • 25%
Below $4 billion • 25%
$4 billion to $4.5 billion • 25%
$4.5 billion to $5 billion • 25%
Above $5 billion • 25%
Less than $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
More than $2 billion • 25%